Advisors Asset Management Inc. lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 20.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,697 shares of the biotechnology company’s stock after selling 708 shares during the period. Advisors Asset Management Inc.’s holdings in United Therapeutics were worth $316,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Quantbot Technologies LP grew its holdings in United Therapeutics by 537.3% during the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 822 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in United Therapeutics by 11.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 351,723 shares of the biotechnology company’s stock valued at $41,219,000 after purchasing an additional 36,522 shares in the last quarter. Rhumbline Advisers grew its holdings in United Therapeutics by 9.4% during the 3rd quarter. Rhumbline Advisers now owns 87,979 shares of the biotechnology company’s stock valued at $10,310,000 after purchasing an additional 7,582 shares in the last quarter. Toronto Dominion Bank grew its holdings in United Therapeutics by 244.7% during the 3rd quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,351 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in United Therapeutics by 35.7% during the 3rd quarter. Sei Investments Co. now owns 8,005 shares of the biotechnology company’s stock valued at $938,000 after purchasing an additional 2,107 shares in the last quarter. 99.94% of the stock is currently owned by institutional investors.

A number of equities research analysts recently weighed in on the stock. ValuEngine raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 30th. BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. TheStreet downgraded shares of United Therapeutics from a “b-” rating to a “c” rating in a research note on Friday, September 29th. HC Wainwright reiterated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics in a research note on Thursday, October 26th. Finally, Cowen reiterated a “hold” rating and set a $129.00 price objective on shares of United Therapeutics in a research note on Friday, October 27th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $136.10.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at $134.24 on Thursday. The firm has a market cap of $5,791.15, a PE ratio of 11.82 and a beta of 1.42. United Therapeutics Corporation has a 52-week low of $112.01 and a 52-week high of $169.89.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million for the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period last year, the firm posted $4.23 EPS. sell-side analysts expect that United Therapeutics Corporation will post 12.45 EPS for the current year.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,241 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $128.95, for a total transaction of $160,026.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,274 shares of the firm’s stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $116.07, for a total transaction of $147,873.18. Following the transaction, the chief executive officer now directly owns 2,343 shares in the company, valued at approximately $271,952.01. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,088 shares of company stock worth $2,677,269. 7.80% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “United Therapeutics Corporation (UTHR) Holdings Trimmed by Advisors Asset Management Inc.” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/07/united-therapeutics-corporation-uthr-holdings-trimmed-by-advisors-asset-management-inc.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.